Research
Three-year data supports extended treatment of Syfovre for GA
Phase 3 GALE study results indicate a continued reduction in GA lesion growth.
Products
Positive 24-month data released for phase 3 trials on Syfovre
Latest data supports the FDA-approved therapeutic for treating GA.Products
CMS assigns Syfovre a permanent J-code
Formulation is the first and only treatment FDA-approved for geographic atrophy secondary to AMD.
Business
Apellis to reduce workforce in support of Syfovre growth, prioritize research initiatives
Company details plans for Syfovre and systemic pegcetacoplan, with a focus on novel therapies for retina and central nervous system diseases.Products
Apellis reports update on Syfovre-associated retinal vasculitis cases
Company is also notifying clinicians to discontinue use of 19-gauge filter needles included in certain injection kits.
Products
Extension study reinforces Syfovre long-term efficacy for GA
Thirty-month data supports the FDA-approved drug’s use for GA patients.
Products
Apellis releases update on review of Syfovre retinal vasculitis cases
Company reports findings from ongoing investigation into cases following drug’s FDA approval; releases new extension study data.Products
ASRS reports safety concerns over Apellis' Syfovre
A reported six cases of retinal vasculitis have occurred in patients following the first intravitreal injection, the organization says.
Research
Apellis publishes phase 3 post-hoc analyses on Syfovre for GA
Analysis on 24-month data found visual function and quality-of-life benefits for patients.
Products
FDA approves Syfovre for GA treatment
Apellis’s pegcetacoplan injection is now the first and only approved option for patients with GA secondary to AMD.
Pipeline